CCL14a/HCC-1 Antibody [Alexa Fluor® 700]

• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 700

CCL14a/HCC-1 Antibody [Alexa Fluor® 700] Summary

• Immunogen: E. coli-derived recombinant human CCL14a/HCC‑1
  Thr20-Asn93
  Accession # Q16627
• Specificity: Detects human CCL14a/HCC‑1 in direct ELISAs and Western blots. In direct ELISAs and Western blots (non-reducing conditions), less than 5% cross-reactivity with recombinant human (rh) MCP-2, rhMCP-3, recombinant mouse (rm) C10, and rmMIP-1 beta
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

HCC-1 (Hemofiltrate CC Chemokine-1) was originally isolated from the hemofiltrate of human patients with chronic renal failure (1). It belongs to the CC chemokine superfamily and has been designated CCL14a. HCC-1/CCL14a cDNA encodes a 93 amino acid (aa) residue  precursor with a 19 aa signal peptide that is cleaved to form the 74 aa secreted protein (aa 20‑93). By alternative splicing, a second longer isoform named HCC-3/CCL14b, which includes sequences from exon 3, also exists (2). HCC-1/CCL14a is expressed constitutively in various normal tissues including spleen, liver, muscle, gut and bone marrow. It circulates at nanomolar concentrations in human plasma. Different post-translationally modified HCC-1/CCL14a, including O-glycosylated and N-terminally truncated variants of HCC‑1/CCL14a, have been identified (3, 4). Whereas the 74 aa peptide is a weak CCR1 agonist, the proteolytically processed, truncated HCC‑1/CCL14a (aa 28‑93) is a highly potent agonist of CCR1, CCR5 and to a lesser extent, CCR3. HCC-1/CCL14a (aa 28‑93) promotes chemotaxis of T lymphocytes, monocytes and eosinophils, and inhibits infection of M-tropic human immunodeficiency virus type 1. Activation of the HCC-1/CCL14a precursor to active peptide is mediated by the urokinase type plasminogen activator or plasmin (5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.